Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Chronic Sildenafil for Severe Diaphragmatic Hernia

Phase 4

Terminated

Conditions: Hypertension, Pulmonary
Hypoplasia, Pulmonary
Hernia, Diaphragmatic

Interventions: Drug: Placebo
Drug: sildenafil

First Posted Date: 2005-08-23

Last Posted Date: 2021-01-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT00133679

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco Children's Hospital, San Francisco, California, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

Treatment of Latent TB Infection for Jailed Persons

Phase 3

Completed

Conditions: Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifampin

First Posted Date: 2005-08-09

Last Posted Date: 2020-07-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 364

Registration Number: NCT00128206

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-08-04

Last Posted Date: 2012-09-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 53

Registration Number: NCT00126633

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Longitudinal Antimalarial Combinations in Uganda

Phase 3

Completed

Conditions: Malaria

Interventions: Drug: Artemether+Lumefantrine
Drug: Amodiaquine+Artesunate
Drug: Amodiaquine+Sulfadoxine/Pyrimethamine

First Posted Date: 2005-07-25

Last Posted Date: 2020-06-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 601

Registration Number: NCT00123552

Locations: 🇺🇬
Assessment Center - Mulago Hospital, Kampala, Uganda

Effectiveness of the Diaphragm for HIV Prevention

Phase 3

Withdrawn

Conditions: HIV Infection

First Posted Date: 2005-07-21

Last Posted Date: 2015-03-04

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00121459

Locations: 🇿🇦
Perinatal HIV Research Unit, Soweto, Gauteng, South Africa
🇿🇦
Medical Research Council of South Africa, Durban, KwaZulu Natal, South Africa
🇿🇼
UZ-UCSF, Harare, Zimbabwe

Activated Protein C to Treat Acute Lung Injuries

Phase 2

Terminated

Conditions: Respiratory Distress Syndrome, Adult

First Posted Date: 2005-05-30

Last Posted Date: 2014-03-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 90

Registration Number: NCT00112164

Locations: 🇺🇸
University of California San Francisco at Fresno, Fresno, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

and more 6 locations

LGBT Internet Based Smoking Treatment - 1

Phase 3

Completed

Conditions: Tobacco Use Disorder

First Posted Date: 2005-05-23

Last Posted Date: 2015-03-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 792

Registration Number: NCT00111501

Locations: 🇺🇸
University of California San Francisco Medical Cen, San Francisco, California, United States

Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

Phase 1

Conditions: Head and Neck Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2013-09-20

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00103155

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2014-01-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT00098852

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Lung Cancer
Neurotoxicity

First Posted Date: 2004-09-06

Last Posted Date: 2012-09-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 80

Registration Number: NCT00003072

Locations: 🇺🇸
Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
UCSF/Mt. Zion Cancer Center, San Francisco, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy